Biosimilars LatAm – Mexico 2025
Designed to advance greater access to biosimilars in Mexico, this forum convenes top decision-makers from manufacturers, regulators, and healthcare providers. Featuring dynamic presentations, interactive panels, and networking spaces, the event delves into policy reforms, investment strategies, and environmental sustainability in biosimilar production. The forum also explores innovative regulatory approaches and public-private collaborations aimed at accelerating approvals and improving affordability, reinforcing Mexico’s competitive position in the biotechnology sector.
Key Objectives:
– Evaluate policies to expand biosimilar access for vulnerable populations and redistribute healthcare savings to improve equity.
– Analyze strategies to position Mexico as a competitive destination for biotechnology investments, exploring regulatory and market opportunities.
– Discuss environmental challenges in biosimilar production and explore solutions for sustainable manufacturing practices aligned with global goals. – Explore strategies to accelerate biosimilar approvals in Mexico, maintaining safety and efficacy standards while fostering public-private partnerships.
.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Plan Your 1-to-1 Meetings with JackLeckerman App
1. JackLeckerman App: Login & Meeting Notifications
Download the JackLeckerman App and sign up.
Check your email for the login details, or use the “Forgot Password” option to retrieve them.
You will receive meeting reminders on your mobile over the 2 days.
These reminders will include meeting requests, meeting confirmations, and messages from other attendees and the coordinator.
2. Attendee list to Plan Your Meetings
Browse the attendee list and select someone for a 10-minute 1-to-1 Meeting request.
Meeting requests close one hour before each Networking session in the program.
3. Managing Meeting Requests, Your Meetings Schedule
Accept or decline meeting requests through the “Meetings” button.
Check your scheduled meetings for the upcoming networking break.
4. Meeting Point Location in the Coffee Break Area
Go to the coffee break area and find the table number to meet your colleague
Speaker Board 2024
Gloria Berrutti
Director of International Business Latam
Patrick Devlyn
President Healthcare Commission
José Avalos Rogel
General Director
Raman Wattamwar
CEO
Pedro Pablo Chavarría Juárez
Regulatory Affairs Director
Talita Ferreira
Consultant
Fernando Portugal
Director of Intellectual Property, Legal and International Affairs
Meenu Wadhwa
Section Leader, Cytokines & Growth Factors Section
Eduardo Perusquia García
Director of New Developments & Quality
Antonio Eduardo Sánchez García
VP of Public Policies for Devices
Oscar César Bustamante García
Regulatory Affairs Manager
Maria Yolanda Cervantes Apolinar
Senior Consultant and Expert in Vaccines
Vinicius Marçal
Business Development Manager
Haleh Hamedifar
Chairperson
Mauricio Barrón
Customer Application Specialist
Mario Novoa Belman
Sales & Application Specialist
Stephan Jarpa Cuadra
Director
Ximena Marcela Bonilla Forero
Research Leader Pharmaceutical Biotechnology Unit
Irma Garcia Morales
Regional Compliance Head Mexico & LATAM
Fernando Goicoechea Romero
General Manager LatAm
Rodrigo Ruíz Ramírez
Senior Manager Pharmacovigilance
Nestor Perez
COO and R&D Director
Oscar Raziel Gamiz Vargas
Sr. Marketing Manager Pharmaceutical Systems LATAM
Sonia Mayra Pérez Tapia
Executive Director
Jaime Uribe
Member of Biosimilars Committee
Fernando Fon
Director Medical and Regulatory Affairs
Jonathan Pablo Aceves Martinez
Global Regulatory Affairs Director, Regulatory Science
Program at a Glance
Biosimilar Regulatory Updates
Access and Equity: Ensuring Biosimilars Reach Those Who Need Them Most
This panel will evaluate policies for expanding access to biosimilars among vulnerable populations, discussing effective frameworks for redistributing healthcare savings to improve equity.
Data Box: Impact of Biosimilars on Access to Oncology Treatments in the Last Five Years
This session will analyze how the introduction of biosimilars has influenced the availability and access to oncology drugs in various health systems. Using examples from Spain and other countries, it will highlight the potential of these therapies to generate significant savings and improve healthcare coverage in Mexico.
Data Box: Internet of Things (IoT) for Equipment Monitoring
This session will showcase key data on how IoT technologies are revolutionizing equipment monitoring in the pharmaceutical sector. It will highlight real-time insights, predictive maintenance, and their implications for reducing operational downtime and improving efficiency.
Data Box: Adoption of Biosimilars in Latin America: A Focus on Economic Access
An analysis of biosimilar adoption in regional markets like Brazil and Colombia, focusing on achieved clinical outcomes and cost reductions for healthcare systems. Lessons will be drawn for Mexico, considering its unique regulatory and economic context.
Attracting Investments for Biosimilars: A Roadmap for Mexico
This panel will analyze strategies to position Mexico as a competitive destination for investments in biotechnology. Panelists will discuss investment trends, market opportunities, and the role of regulation in fostering a favorable business environment.
Data Box: Intellectual property of medicines: a changing challenge
This session will review biosimilar approval timelines in the United States, Europe, and Mexico, analyzing how differences in regulation affect access and competitiveness. The importance of aligning Mexico’s regulatory processes with international standards will also be discussed.
Sustainable Biosimilar Manufacturing: Reducing Carbon Footprint and Environmental Impact
This panel will discuss the environmental challenges associated with biosimilar production, including water consumption, waste management, and carbon emissions. Panelists will explore innovative solutions to reduce the ecological footprint of manufacturing processes and align with global sustainability goals. Topics will include regulatory incentives for green production and industry best practices.
Regulatory Innovation for Faster Biosimilar Approvals in Mexico
This panel will explore innovative strategies to reduce the time required for biosimilar approvals in Mexico while maintaining safety and efficacy standards. Discussions will include global best practices, necessary policy changes, and the role of public-private partnerships.
Full Programme in the PDF Agenda
Download Agenda
Sponsors
Photo Gallery from Previous Events
Testimonials
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico